Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902764 | 0.90 | L3MBTL1 (0.49) | BCHEL3MBTL1NTSR1 | |
| SCHEMBL31365850 | 0.87 | LMNA (0.51) | BCHEACHECTSSCTSKCAPN1 | |
| SCHEMBL30902823 | 0.87 | REN (0.55) | CTSDRENCTSSCTSKPSMB5 | |
| SCHEMBL25132765 | 0.86 | SYK (0.49) | BCHEACHECTSSCTSKPSMB5 | |
| SCHEMBL30902909 | 0.86 | GLP1R (0.43) | BCHEACHECTSSCTSKCAPN1 | |
| SCHEMBL29548828 | 0.79 | PSMB5 (0.53) | RENBCHEACHECTSKPSMB5 | |
| SCHEMBL25134164 | 0.79 | SYK (0.56) | BCHEACHECTSSCTSKPSMB5 | |
| SCHEMBL31235831 | 0.79 | SIRT2 (0.46) | BCHEACHECTSSCTSKCAPN1 | |
| SCHEMBL11911350 | 0.79 | SYK (0.54) | CTSSCTSKL3MBTL1NTSR1 | |
| SCHEMBL10051906 | 0.79 | SYK (0.54) | CTSSCTSKL3MBTL1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |